BridgeBio Oncology Therapeutics
Yahoo Finance • 2 months ago
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?
Key Points Cormorant Asset Management added 251,600 shares in Rapport Therapeutics; the reported position value increased by approximately $61.38 million over the prior quarter. The change represents 0.31% of Cormorant’s reportable 13F as... Full story
Yahoo Finance • 2 months ago
BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded an i... Full story
Yahoo Finance • 3 months ago
BBOT to Participate in Upcoming December Investor Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of... Full story
Yahoo Finance • 3 months ago
Alphabet’s Secret Portfolio Just Bought These 2 Stocks. Should You Buy Too?
24/7 Wall St. Quick Read Alphabet (GOOG,GOOGL) holds a portfolio of 37 stocks worth $2.5B to $3B through its venture arms GV and CapitalG. Google’s portfolio is heavily tilted toward healthcare and biotech with its largest holding being... Full story
Yahoo Finance • 3 months ago
BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced two poster pres... Full story
Yahoo Finance • 4 months ago
Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglycemia
Data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα and strongly inhibits pAKT signaling in tumor cells without affecting glucose metabolismRobust monotherapy activity, as well as combination activity with BBOT’s KRASG12C ON... Full story
Yahoo Finance • 4 months ago
BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced poster presenta... Full story
Yahoo Finance • 5 months ago
BridgeBio started at outperform at Leerink on 'differentiated' oncology platform
[Wall street.] bodrumsurf * Leerink Partners initiated BridgeBio Oncology Therapeutics (NASDAQ:BBOT [https://seekingalpha.com/symbol/BBOT]) at outperform saying that the biotech has a "differentiated precision oncology platform." * Th... Full story
Yahoo Finance • 6 months ago
BBOT to Participate in Upcoming September Investor Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of... Full story
